VWA5A anticorps

N° du produit ABIN7240895

Détail du produit anti-VWA5A anticorps

Antigène: VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VWA5A est non-conjugé

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC)

Attributs du produit: Polyclonal Antibody

Purification: Affinity purification

Immunogène: Recombinant protein of human VWA5A

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000, IHC 1:100-1:300

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: PBS with 0.05 % sodium azide and 50 % glycerol, PH7.4

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Avoid freeze / thaw cycles.

Détails sur VWA5A

Antigène: VWA5A (Von Willebrand Factor A Domain Containing 5A (VWA5A))

Autre désignation: VWA5A (VWA5A Produits)

Synonymes: anticorps VWA5A, anticorps LOH11CR2A, anticorps MGC68953, anticorps loh11cr2a, anticorps BCSC-1, anticorps BCSC1, anticorps 5830475I06Rik, anticorps AW552491, anticorps E130119J22, anticorps Loh11cr2a, anticorps masa-1, anticorps loss of heterozygosity, 11, chromosomal region 2, gene A, anticorps von Willebrand factor A domain containing 5A, anticorps von Willebrand factor A domain containing 5A S homeolog, anticorps LOH11CR2A, anticorps VWA5A, anticorps vwa5a.S, anticorps vwa5a, anticorps Vwa5a

Sujet: VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80 % of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.

Poids moléculaire: 86 kDa

UniProt: O00534